0001415889-22-012993.txt : 20221227
0001415889-22-012993.hdr.sgml : 20221227
20221227171652
ACCESSION NUMBER: 0001415889-22-012993
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220520
FILED AS OF DATE: 20221227
DATE AS OF CHANGE: 20221227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Enyedy Mark J
CENTRAL INDEX KEY: 0001586965
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17999
FILM NUMBER: 221491053
MAIL ADDRESS:
STREET 1: C/O FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ImmunoGen, Inc.
CENTRAL INDEX KEY: 0000855654
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042726691
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 830 WINTER ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781)895-0600
MAIL ADDRESS:
STREET 1: 830 WINTER ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUNOGEN INC
DATE OF NAME CHANGE: 19920703
4
1
form4-12272022_101239.xml
X0306
4
2022-05-20
0000855654
ImmunoGen, Inc.
IMGN
0001586965
Enyedy Mark J
C/O IMMUNOGEN, INC.
830 WINTER STREET
WALTHAM
MA
02451
true
true
false
false
CHIEF EXECUTIVE OFFICER
Stock Option (Right to Buy)
4.55
2022-05-20
4
A
0
393750
0
A
2022-05-20
2030-02-07
Common Stock
393750
393750
D
Stock Option (Right to Buy)
4.55
2022-11-14
4
A
0
787500
0
A
2022-11-14
2030-02-07
Common Stock
787500
1181250
D
On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.
On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.
/s/ Renee Lentini, Attorney-in-Fact
2022-12-27